Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Annals of Nuclear Medicine
Erschienen in: Annals of Nuclear Medicine 7/2010

01.08.2010 | Original Article

A meta-analysis of 18F-Fluoride positron emission tomography for assessment of metastatic bone tumor

verfasst von: Ukihide Tateishi, Satoshi Morita, Masataka Taguri, Kazuya Shizukuishi, Ryogo Minamimoto, Masashi Kawaguchi, Takeshi Murano, Takashi Terauchi, Tomio Inoue, E. Edmund Kim

Erschienen in: Annals of Nuclear Medicine | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to assess the diagnostic performance of 18F-Fluoride positron emission tomography (PET) or positron emission tomography/computed tomography (PET/CT) compared with bone scintigraphy (BS) planar or BS planar and single photon emission computed tomography (SPECT) in evaluating patients with metastatic bone tumor.

Materials and methods

We performed a meta-analysis of all available studies addressing the diagnostic accuracy of 18F-Fluoride PET, 18F-Fluoride PET/CT, BS planar, and BS planar and SPECT for detecting the metastatic bone tumor. We determined sensitivities and specificities across studies, calculated positive and negative likelihood ratios, and drew summary receiver operating characteristic curves using hierarchical regression models. We also compared the effective dose and cost-effectiveness estimated by data from the enrolled studies between 18F-Fluoride PET or PET/CT and BS planar or BS planar and SPECT.

Results

When comparing all studies with data on 18F-Fluoride PET or PET/CT, sensitivity and specificity were 96.2% [95% confidence interval (CI) 93.5–98.9%] and 98.5% (95% CI 97.0–100%), respectively, on a patient basis and 96.9% (95% CI 95.9–98.0%) and 98.0% (95% CI 97.1–98.9%), respectively, on a lesion basis. The Az values of 18F-Fluoride PET or PET/CT were 0.986 for the patient basis and 0.905 for the lesion basis, whereas those of BS or BS and SPECT were 0.866 for the patient basis and 0.854 for the lesion basis. However, the estimated effective dose and average cost-effective ratio were poorer for 18F-Fluoride PET or PET/CT than those of BS planar or BS planar and SPECT.

Conclusion

18F-Fluoride PET or PET/CT has excellent diagnostic performance for the detection of metastatic bone tumor, but the estimated effective dose and average cost-effective ratio are at a disadvantage compared with BS planar or BS planar and SPECT.
Literatur
1.
Ghanem N, Uhl M, Brink I, Schäfer O, Kelly T, Moser E, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol. 2005;55:41–55.CrossRefPubMed
2.
Goudarzi B, Kishimoto R, Komatsu S, Ishikawa H, Yoshikawa K, Kandatsu S, et al. Detection of bone metastases using diffusion weighted magnetic resonance imaging: comparison with 11C-methionine PET and bone scintigraphy. Magn Reson Imaging. 2010 (in press).
3.
Vallabhajosula S. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med. 2007;37:400–19.CrossRefPubMed
4.
Cook GJ, Fogelman I. Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography. Q J Nucl Med. 2001;45:47–52.PubMed
5.
Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49:68–78.CrossRefPubMed
6.
Even-Sapir E, Mishani E, Flusser G, Metser U. 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med. 2007;37:462–9.CrossRefPubMed
7.
8.
Murano T, Tateishi U, Iinuma T, Shimada N, Daisaki H, Terauchi T, et al. Evaluation of the risk of radiation exposure from new 18FDG PET/CT plans versus conventional x-ray plans in patients with pediatric cancers. Ann Nucl Med. 2010;24(4):261–7.
9.
Jones D, Shrimpton P. NRPB-SR250: normalised organ doses for X-ray computed tomography calculated using Monte Carlo techniques. National Radiological Protection Board. 1993.
10.
International Commission on Radiological Protection. 1990 recommendations of the International Commission on Radiological Protection. ICRP publication 60. Annals of the ICRP, vol 21, issue 1–3. Oxford: Elsevier; 1991.
11.
Hetzel M, Arslandemir C, König HH, Buck AK, Nüssle K, Glatting G, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res. 2003;18:2206–14.CrossRefPubMed
12.
Hoh CK, Hawkins RA, Dahlbom M, Glaspy JA, Seeger LL, Choi Y, et al. Whole body skeletal imaging with [18F]fluoride ion and PET. J Comput Assist Tomogr. 1993;17:34–41.CrossRefPubMed
13.
Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? Radiology. 1998;209:253–8.PubMed
14.
Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kühn T, Kreienberg R, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17:2381–9.PubMed
15.
Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med. 1999;40:1623–9.PubMed
16.
Schirrmeister H, Glatting G, Hetzel J, Nüssle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800–4.PubMed
17.
Even-Sapir E, Metser U, Flusser G, Kollender Y, Lerman H, Lievshitz G, et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2004;45:272–8.PubMed
18.
Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.PubMed
19.
Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35:1766–74.CrossRefPubMed
20.
Kawaguchi M, Tateishi U, Shizukuishi K, Suzuki A, Inoue T. F-18 fluoride uptake in bone metastasis: morphologic and metabolic analysis on integrated PET/CT. Ann Nucl Med. 2010;24(4):241–7.
21.
Iagaru A, Mittra E, Yaghoubi SS, Dick DW, Quon A, Goris ML, et al. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med. 2009;50:501–5.CrossRefPubMed
22.
Nemeth AJ, Henson JW, Mullins ME, Gonzalez RG, Shaefer PW. Improved detection of skull metastasis with diffusion-weighted MR imaging. Am J Neuroradiol. 2007;28:1088–92.CrossRefPubMed
Metadaten
Titel
A meta-analysis of 18F-Fluoride positron emission tomography for assessment of metastatic bone tumor
verfasst von
Ukihide Tateishi
Satoshi Morita
Masataka Taguri
Kazuya Shizukuishi
Ryogo Minamimoto
Masashi Kawaguchi
Takeshi Murano
Takashi Terauchi
Tomio Inoue
E. Edmund Kim
Publikationsdatum
01.08.2010
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 7/2010
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-010-0393-7

Weitere Artikel der Ausgabe 7/2010

Annals of Nuclear Medicine 7/2010 Zur Ausgabe

Short Communication

Optimum emission time in deep-inspiration breath-hold PET–CT: a preliminary result

Case Report

Intussusception incidentally detected by FDG-PET/CT in a pediatric lymphoma patient

Original Article

The clinical application value of PET/CT in adenocarcinoma with bronchioloalveolar carcinoma features

Original Article

Assessment of VEGF-D expression measured by immunohistochemical staining and F-18 FDG uptake on PET as biological prognostic factors for recurrence in patients with surgically resected lung adenocarcinoma

Case Report

FDG-PET/CT in the evaluation of epithelioid hemangioendothelioma of the liver: the role of dual-time-point imaging. A case presentation and review of the literature

Original Article

Importance of gated CT acquisition for the quantitative improvement of the gated PET/CT in moving phantom